Muscle & Aging
What Does Grip Strength Actually Predict?
The short answer
In a study of 139,691 adults across 17 countries, every 5 kg drop in grip strength was linked to a 16% higher risk of death from any cause and a 17% higher risk of cardiovascular death — grip strength predicted death better than systolic blood pressure did. A separate analysis of 502,293 UK Biobank participants found the same pattern held for cancer and respiratory deaths too. But the relationship isn't perfectly linear: in people with chronic kidney disease, mortality risk actually ticked back up above roughly 28 kg. No trial has tested whether training grip strength itself changes any of these outcomes.
Quick answers
- What is it?
- Grip strength is a simple hand-squeeze measurement that large studies use as a marker of overall muscle and health status.
- Why are people interested in it?
- It's an easy, one-minute test that researchers say predicts death risk better than blood pressure, so people want to know what it can and can't tell them.
- What has actually been studied?
- The PURE study of 139,691 adults across 17 countries, a UK Biobank analysis of 502,293 people, a follow-up study testing absolute versus relative grip measures, a meta-analysis of grip asymmetry in 900,253 people, and a chronic kidney disease dose-response meta-analysis.
- How strong is the evidence?
- Consistent across very large cohorts: every 5 kg drop in grip strength was linked to substantially higher all-cause and cardiovascular mortality across multiple huge studies, though the relationship isn't perfectly linear in people with kidney disease.
- What don't we know yet?
- Whether changing grip strength (through training) actually changes mortality risk — every study is observational — plus the lack of one universal cut-point, the biological mechanism connecting hand strength to organ-specific disease, and why the chronic kidney disease curve turns upward.
- Where can I read the original research?
- Sources at the bottom of this page: Leong DP, Teo KK, Rangarajan S, et al., The Lancet, 2015; and Celis-Morales CA, Welsh P, Lyall DM, et al., BMJ, 2018.
The short answer: Across several large prospective cohorts, a weaker handgrip was consistently linked to a higher risk of dying, independent of age, sex, and other risk factors researchers adjusted for. In the Prospective Urban Rural Epidemiology (PURE) study of 139,691 adults across 17 countries, every 5 kg reduction in grip strength was associated with a 16% higher risk of all-cause mortality and a 17% higher risk of cardiovascular mortality — a stronger association than the study found for systolic blood pressure. A UK Biobank analysis of 502,293 people found the same pattern extended to cancer and respiratory disease deaths. The relationship isn't perfectly linear, though: in people with chronic kidney disease, mortality risk actually rose again above roughly 28 kg of grip strength. And no trial in this search tested whether training grip strength changes any of these outcomes.
What the research shows
A consistent, dose-dependent signal across large cohorts
The PURE study, published in The Lancet in 2015, followed 139,691 people aged 35-70 from urban and rural communities in 17 countries across a range of income levels, for a median of 4.0 years. After adjustment, each 5 kg reduction in grip strength was associated with a 16% higher risk of all-cause mortality (hazard ratio 1.16, 95% CI 1.13-1.20; p<0.0001), a 17% higher risk of cardiovascular mortality (1.17, 1.11-1.24), a 17% higher risk of non-cardiovascular mortality (1.17, 1.12-1.21), a 7% higher risk of myocardial infarction (1.07, 1.02-1.11), and a 9% higher risk of stroke (1.09, 1.05-1.15). The association held across country-income strata. The one counterintuitive finding: in high-income countries, higher grip strength was associated with slightly higher cancer risk (0.916, 95% CI 0.880-0.953, meaning weaker grip was protective for this specific outcome) — a pattern the study did not find in middle- or low-income countries and did not explain.
A 2018 analysis of 502,293 UK Biobank participants published in the BMJ found a similar magnitude of effect and extended it further. Per 5 kg lower grip strength, the hazard ratio for all-cause mortality was 1.20 (95% CI 1.17-1.23) in women and 1.16 (1.15-1.17) in men. The same pattern showed up for cardiovascular mortality (1.19 in women, 1.22 in men), all respiratory disease mortality (1.31 and 1.24), and several site-specific cancers — colorectal, lung, and breast — though not prostate cancer. Adding grip strength to a standard office-based risk score (age, sex, diabetes status, BMI, blood pressure, smoking) modestly improved the score's ability to predict all-cause mortality, cardiovascular mortality, and cardiovascular disease incidence.
How you measure it barely matters
One practical question is whether grip strength should be reported as a raw number (kilograms) or adjusted for body size — since a larger person might be expected to have a stronger grip regardless of muscle quality. A follow-up analysis of 356,721 UK Biobank participants tested this directly, comparing absolute grip strength against grip strength expressed relative to height, weight, fat-free mass, BMI, fat-free mass index, and as standardized z-scores. The associations with mortality and disease incidence did not meaningfully differ across any of these expressions, and none improved risk prediction more than raw kilograms. Over a mean follow-up of 5.0 years, 6,234 of these participants died and 4,523 developed cardiovascular disease.
A newer angle: imbalance between hands
Most research measures grip strength in one hand or averages both. A 2026 systematic review and meta-analysis in Archives of Gerontology and Geriatrics asked a different question: does it matter if your two hands are unequal? Pooling nine cohort studies covering 900,253 participants, the review found that grip strength asymmetry itself was associated with a 12% higher all-cause mortality risk (HR 1.12, 95% CI 1.07-1.17) and a 29% higher cardiovascular mortality risk (1.29, 1.03-1.62) — independent of overall grip strength. When asymmetry was combined with low grip strength in the weaker-performing hand, all-cause mortality risk climbed by 39% (1.39, 1.17-1.65), a stronger signal than either measure alone. The authors described asymmetry as reflecting bilateral neuromuscular coordination rather than raw strength, and proposed it as a complementary, not competing, risk marker.
The kidney-disease exception: a U-shaped curve
Most of the general-population data described above shows mortality risk falling steadily as grip strength rises, with no clear upper bound. A 2024 dose-response meta-analysis in Renal Failure, pooling 18 studies and 4,810 patients with chronic kidney disease (ages 47-71), found something different: a U-shaped curve. Mortality risk fell as grip strength rose from about 10 kg to approximately 28 kg, then ticked back up slightly beyond that point. The authors noted this pattern requires confirmation with disease-stage-specific data, since it could reflect something particular to kidney disease physiology, an artifact of how the pooled studies grouped patients, or something else entirely.
What we don't know yet
Whether changing grip strength changes mortality risk. Every study cited here is observational — grip strength was measured once (or occasionally twice) and people were then followed forward. None of them tested whether an intervention that raises grip strength — resistance training, protein supplementation, or anything else — actually lowers death risk. Grip strength may be a marker of overall health and reserve capacity rather than a modifiable target in itself.
A single cut-point that works across populations. The UK Biobank studies defined weakness as under 26 kg for men and under 16 kg for women, while the kidney-disease meta-analysis found risk bottoming out closer to 28 kg. No retrieved study established one threshold that generalizes across ages, sexes, ethnicities, and disease states.
The biological mechanism connecting hand strength to organ-specific disease. Grip strength predicted deaths from cardiovascular, respiratory, and several cancer causes — a breadth that outstrips any single proposed mechanism (muscle mass, systemic inflammation, frailty, physical activity level) tested directly against mortality in these datasets.
Why the cancer association reversed by income level in the PURE study. Higher grip strength tracked with slightly higher cancer risk in high-income countries only. Nothing in the retrieved data explained this, and it was not replicated or explained in the other cohorts reviewed here.
Why the chronic kidney disease curve turns upward. The dose-response meta-analysis flagged this U-shape but could not determine, from the pooled data, whether it reflects a real physiological ceiling, confounding by disease severity, or limitations in how the underlying studies grouped participants by strength.
Sources
- Leong DP, Teo KK, Rangarajan S, et al. Prognostic value of grip strength: findings from the Prospective Urban Rural Epidemiology (PURE) study. The Lancet, 2015;386(9990):266-273. DOI62000-6)
- Celis-Morales CA, Welsh P, Lyall DM, et al. Associations of grip strength with cardiovascular, respiratory, and cancer outcomes and all cause mortality: prospective cohort study of half a million UK Biobank participants. BMJ, 2018;361:k1651. DOI
- Ho FKW, Celis-Morales CA, Petermann-Rocha F, et al. The association of grip strength with health outcomes does not differ if grip strength is used in absolute or relative terms: a prospective cohort study. Age and Ageing, 2019;48(5):684-691. DOI
- Ran M, Yu Y, Chen L, Zhou X. Handgrip strength asymmetry is associated with mortality risk: Systematic review and meta-analysis. Archives of Gerontology and Geriatrics, 2026;146:106237. DOI
- Chen H, Zhang F, Huang L, Bai Y, Zhong Y, Li Y. Thresholds of handgrip strength for all-cause mortality in patients with chronic kidney disease: a secondary systematic review with dose-response meta-analysis. Renal Failure, 2024;46(1):2305855. DOI
Article records maintained via PubMed. Peptide Proof reports what studies found. It does not provide medical advice, dosing guidance, or treatment recommendations.
Topic: Energy & Performance · Aging & Longevity
Sources
- Prognostic value of grip strength: findings from the Prospective Urban Rural Epidemiology (PURE) study
- The Lancet, 2015 · n=139691 · DOI
- Associations of grip strength with cardiovascular, respiratory, and cancer outcomes and all cause mortality: prospective cohort study of half a million UK Biobank participants
- BMJ, 2018 · n=502293 · DOI
- The association of grip strength with health outcomes does not differ if grip strength is used in absolute or relative terms
- Age and Ageing, 2019 · n=356721 · DOI
- Handgrip strength asymmetry is associated with mortality risk: Systematic review and meta-analysis
- Archives of Gerontology and Geriatrics, 2026 · n=900253 · DOI
- Thresholds of handgrip strength for all-cause mortality in patients with chronic kidney disease: a secondary systematic review with dose-response meta-analysis
- Renal Failure, 2024 · n=4810 · DOI
Get the evidence, not the hype.
New research briefs, plainly written and fully sourced. No dosing advice, ever.